Intracameral medication use requires careful consideration of pros and cons

Article

When thinking about administering medications intracamerally during cataract surgery, it is important to consider whether their potential benefits are worth the risk.

When thinking about administering medications intracamerally during cataract surgery, it is important to consider whether their potential benefits are worth the risk, said Nick Mamalis, MD, at Spotlight on Cataracts 2007.

Intracameral medications may be used in cataract surgery for anesthesia, pupil dilation, and to prevent inflammation and endophthalmitis. Their advantages include ease of delivery, elimination of toxicity of topical drops, avoidance of compliance issues, and possibly enhanced efficacy.

However, there are a number of downsides. Toxicity is an important risk that can occur through multiple mechanisms, which can be related to improper concentration, pH, or osmolarity. In addition, all medications used intracamerally should be preservative-free, but it is also important to be aware of toxicity related to stabilizing agents, such as are found in preservative-free epinephrine. Infectious contamination is another safety concern as is the potential for incompatibility when multiple drugs are combined.

"There are many trade-offs to consider when weighing the pros and cons of using topical drops versus intracameral medications. Intracameral medication safety can be improved if we could eliminate 'kitchen pharmacy,'" Dr. Mamalis said.

"We need sterile, pre-mixed, preservative-free, unit-dose products, and the ophthalmology community needs to work with the FDA and industry to achieve that goal," he added.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.